- NCIt
- C116915
Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05391490 | Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies(KCAT19) | recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | recruiting | Phase 1 / Phase 2 | 31 | Jacqueline Garcia, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 11, 2026source: clinicaltrials
| NCT04955938 |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms |
| withdrawn |
| Phase 1 |
| 0 |
| University of ChicagoOTHER |
| 1 |
| Jul 31, 2024 |
| clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT04419623 | A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer | completed | Phase 1 | 7 | Telios Pharma, Inc.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT01957579 | A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00230321 | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 21 | Peter L GreenbergOTHER | 1 | Feb 4, 2013 | clinicaltrials |